Navigation Links
Biodel Announces Phase 2 Clinical Trial Initiation Of Ultra-Rapid-Acting Insulin Candidate BIOD-123
Date:9/13/2012

DANBURY, Conn., Sept. 13, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced the initiation of a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting mealtime insulin candidate, BIOD-123.  

"We are pleased to achieve another milestone in the development of BIOD-123. We continue to meet our timelines and project that we will be able to communicate top-line Phase 2 safety and efficacy data in the third calendar quarter of 2013," stated Dr. Errol De Souza, president and chief executive officer of Biodel.

Dr. Alan Krasner, Biodel's Chief Medical Officer, stated:  "This Phase 2 study is designed to assess the clinical impact of the ultra-rapid absorption profile of BIOD-123 relative to currently marketed mealtime insulin analogs.  There is room for improvement in the area of mealtime insulin therapy and we are hopeful that this new candidate will help usher in a new insulin class designed to achieve better meal time outcomes for patients with diabetes."

In April 2012, Biodel announced positive top-line results from a Phase 1 clinical trial of BIOD-123, which demonstrated that the formulation had a more rapid absorption than insulin lispro, sold as Humalog®, with comparable injection site tolerability.

The Phase 2 study is a randomized, open label parallel group study enrolling 130 patients with Type 1 diabetes at approximately 30 U.S. investigative centers. The patients are randomized to receive either BIOD-123 or insulin lispro as their mealtime insulin over an 18 week treatment duration. Both arms of the study use insulin glargine, sold as Lantus®, as the basal insulin. The primary endpoint compares changes in HbA1c, while secondary endpoints compare postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.

A
'/>"/>

SOURCE Biodel Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
2. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
3. Biodel to Present at 2012 Wedbush PacGrow Lifesciences Management Access Conference
4. BioDelivery Sciences to Present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference
5. BioDelivery Sciences and Endo Health Solutions Announce Initiation of Enrollment in the Phase 3 Program for BEMA Buprenorphine for Chronic Pain
6. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
7. BioDelivery Sciences Announces Positive Results from BEMA Buprenorphine/Naloxone (BNX) Pharmacokinetic Study
8. Biodel Announces $18.5 Million Private Placement
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
11. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...  In recognition of the increased risks that ... flu, pneumonia, shingles and other illnesses, CVS/pharmacy ® ... to be Senior Vaccination Month. Because people,s immune ... that adults ages 65 years and older stay ... and MinuteClinic nurse practitioners and physician assistants will ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... , Aug. 28, 2014 Telik, Inc. (OTCQB: ... that merged with MabVax Therapeutics, Inc. on July ... progress related to the development of its lead ... recovered using the Company,s internally developed antibody discovery ... for multiple antibody based therapeutic and diagnostic products ...
Breaking Medicine Technology:September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
... report is available in its catalogue: , , , ... , , http://www.reportlinker.com/p0191978/China-Patient-Monitoring-Market-Outlook-to-2016.html ... China Patient Monitoring Market Outlook to 2016 , , , ... , , "China Patient Monitoring Market Outlook ...
... June 1 Clinicians at Institut Catala d,Oncologia (ICO) in ... using RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate ... the country to receive the fast and efficient treatment. , ... "The treatment went very well and the ...
Cached Medicine Technology:Reportlinker Adds China Patient Monitoring Market Outlook to 2016 2Reportlinker Adds China Patient Monitoring Market Outlook to 2016 3Reportlinker Adds China Patient Monitoring Market Outlook to 2016 4Reportlinker Adds China Patient Monitoring Market Outlook to 2016 5Reportlinker Adds China Patient Monitoring Market Outlook to 2016 6Reportlinker Adds China Patient Monitoring Market Outlook to 2016 7Reportlinker Adds China Patient Monitoring Market Outlook to 2016 8Reportlinker Adds China Patient Monitoring Market Outlook to 2016 9Reportlinker Adds China Patient Monitoring Market Outlook to 2016 10Reportlinker Adds China Patient Monitoring Market Outlook to 2016 11Reportlinker Adds China Patient Monitoring Market Outlook to 2016 12Reportlinker Adds China Patient Monitoring Market Outlook to 2016 13Reportlinker Adds China Patient Monitoring Market Outlook to 2016 14Reportlinker Adds China Patient Monitoring Market Outlook to 2016 15Reportlinker Adds China Patient Monitoring Market Outlook to 2016 16Reportlinker Adds China Patient Monitoring Market Outlook to 2016 17Reportlinker Adds China Patient Monitoring Market Outlook to 2016 18Reportlinker Adds China Patient Monitoring Market Outlook to 2016 19Reportlinker Adds China Patient Monitoring Market Outlook to 2016 20Reportlinker Adds China Patient Monitoring Market Outlook to 2016 21Reportlinker Adds China Patient Monitoring Market Outlook to 2016 22Reportlinker Adds China Patient Monitoring Market Outlook to 2016 23Reportlinker Adds China Patient Monitoring Market Outlook to 2016 24Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 2Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 3Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian 4
(Date:8/28/2014)... August 28, 2014 Gurnick Academy of ... Technology program is re-accredited for the 5 years of ... Imaging Technologists (ARMRIT). , “We are very proud ... improving our program to make sure we provide the ... of interest in MRI field nowadays and I look ...
(Date:8/28/2014)... Amy Norton HealthDay Reporter ... have found that sending electrical currents through the scalp to ... for up to a day. In a small study ... to fire up certain networks involved in memory. That, in ... apparent 24 hours after the brain stimulation. During TMS, ...
(Date:8/28/2014)... "stuck fermentation," when yeast that should be busily converting ... down, leaving the remaining sugar to instead be consumed ... team of researchers including UC Davis yeast geneticist Linda ... problem. Working through a prion -- an abnormally ... enables bacteria in fermenting wine to switch yeast from ...
(Date:8/28/2014)... August 28, 2014 Data from the ... that while most hospitals utilize a basic electronic health ... information technology is still a challenge. , This ... August issue of Health Affairs , and is co-authored ... Care Data Center, as well as Chantal Worzala, director ...
(Date:8/28/2014)... Tenn. The New England Journal of Medicine ... clinical trial of a drug shown to safely reduce ... volunteers intranasally infected with respiratory syncytial virus (RSV). ... of Tennessee Health Science Center researcher Infectious Disease Specialist ... , RSV is the most common cause ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:DeVincenzo study breakthrough in RSV research 2
... is serving up a surprise not only for tomato lovers ... rod-shaped bacterium that causes misery for millions of people. , ... PloS One , researchers say they,ve identified a molecular trick ... from the University of Rochester Medical Center has identified a ...
... has entered,into a binding agreement to purchase the ... MSC, which previously consisted of two,distinct units -- ... brand and,all employees, products and services not associated ... ESRX ) is one of the largest ...
... days to try to resolve remaining issues, TORONTO, ... PMD; Amex: PME) today announced that the Company has ... (FDA) in an,effort to resolve the outstanding issues associated ... test. Over the,next 60 days PreMD and the FDA ...
... research shows , , FRIDAY, June 13 (HealthDay News) -- ... the morning may help ease some stresses you might ... rats inhaled the aroma of roasted coffee beans, a ... proteins with healthful antioxidant activity, the researchers reported. ...
... June 13 The Blinded,American Veterans Foundation (BAVF), at ... Maryland State Delegate Sheila Hixson., "We,re honored to ... of Maryland,s District 20 and to the entire State ... MD. "Her,tireless efforts as a legislator and community activist ...
... more reliable detection of Chlamydia trachomatis, the most ... disease in Europe., PLEASANTON, Calif., June 13 ... Chlamydia trachomatis has received CE Mark,certification, allowing it to ... is designed with a dual target approach to help ...
Cached Medicine News:Health News:Salmonella: Trickier than we imagined 2Health News:Salmonella: Trickier than we imagined 3Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 2Health News:Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 3Health News:PreMD Reports Further Positive Meetings with the FDA 2Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3
Stryker bariatric laparoscopes set the standard in picture quality....
The flexible nature of the vinyl allows the user to reach deeper into the chamber and allows for a greater comfort when working inside the glove box over a long period of time compared to any rigid s...
Compact, economical Bactron II anaerobic environment system with air lock, workspace and a 200 plate capacity incubator delivers optimum productivity in a compact space....
... Bactron I is an ... designed for use by smaller ... as an economical set-up station ... quality features of other Bactron ...
Medicine Products: